Akebia Therapeutics Inc — Liquidità Trimestrale (NASDAQ:AKBA) | MetaTrader

Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 220.67 M310.19 M345.6 M364.15 M376.56 M362.52 M Totale passività 269.86 M285.6 M316.37 M322.56 M343.95 M335.14 M Patrimonio netto totale -49.19 M24.58 M29.22 M41.59 M32.61 M27.38 M Totale passività e patrimonio netto 220.67 M310.19 M345.6 M364.15 M376.56 M362.52 M Debito totale 38.69 M46.51 M47.06 M47.64 M48.25 M48.89 M Indebitamento netto 38.69 M46.51 M-90.25 M-118.8 M-136.59 M-113.75 M

Notizie

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

Relazione sugli utili: i risultati di Akebia nel Q1 2026 deludono le previsioni, il titolo crolla

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Are Options Traders Betting on a Big Move in Akebia Therapeutics Stock?

New Strong Sell Stocks for April 28th

Leerink conferma il rating su Akebia per precedente regolatorio

H.C. Wainwright conferma il rating buy su Akebia Therapeutics

Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day - Slideshow (NASDAQ:AKBA) 2026-04-04

Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript

Akebia Therapeutics nomina Philip Vickers nel consiglio di amministrazione